http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
IgE and anti-IgE therapy in asthma and allergic disease
Introduction -- Serum IgE distributions in normal and asthmatic subjects -- Understanding the binding of IgE to its high-affinity receptor and to an anti-IgE antibody -- Mediator release from basophils and mast cells and its relationship to FceRI expression and IgE-suppressing therapies -- Expression of IgE receptors on eosinophils -- Eosinophil IgE receptors : controversy and consensus -- Murine models of asthma : caveats and conclusions on the contribution of IgE and mast cells to allergic inflammation, airway hyperresponsiveness, and airflow obstruction -- Role of IgE in asthma : pathogenesis and novel therapeutic strategies -- IgE-mediated response to allergen in the bronchoprovocation laboratory -- Pathophysiology of the airway response to inhaled allergen in asthmatic subjects : role of IgE -- Efficacy and safety of xolair anti-IgE monoclonal antibody in adult asthmatics -- The role of IgE in pediatric asthma -- Anti-inflammatory activities of omalizumab (xolair), a recombinant humanized monoclonal antibody binding IgE -- Pulmonary delivery of anti-IgE : rationale for topical delivery to the airway -- Treatment of seasonal allergic rhinitis -- Anti-IgE and allergic skin diseases -- Role of IgE and food allergens -- Role of IgE in allergic bronchopulmonary aaspergillosis -- IgE and its role in parasitic helminth infection : implications for anti-IgE-bassed therapies -- The rise of antibodies as therapeutics
edited by Robert B. Fick, Jr., Paula M. Jardieu.
Includes bibliographical references and indexes.
Lung biology in health and disease ; v. 164